Factors Affecting Uptake and Distribution of Volatile Anesthetic Agents

Core Concept: FA/FI Ratio

"The faster the uptake of anesthetic agent, the greater the difference between inspired and alveolar concentrations and the slower the rate of induction." - Morgan and Mikhail's Clinical Anesthesiology, 7e

I. FACTORS AFFECTING UPTAKE

A. Factors That Increase FA (Speed Up Induction)

1. Inspired Concentration (FI) - The Concentration Effect

• A higher inspired concentration raises FA more rapidly.
• The concentration effect has two components:
  • Concentrating effect: As anesthetic molecules are absorbed, the remaining gas is "concentrated" - e.g., if 80% N2O is delivered and half is absorbed, the remaining alveolar volume contracts and the concentration increases from 80% to >80%.
  • Augmented inflow: Gas uptake creates a slight negative pressure that draws more fresh gas into the alveoli, increasing the effective ventilation.
• This effect is most significant with nitrous oxide (because it can be delivered in high concentrations) and less prominent with volatile agents.

2. Second Gas Effect

• When a large volume of a primary gas (N2O) is absorbed, it accelerates the uptake of a simultaneously delivered second gas (e.g., sevoflurane) by:
  • Concentrating it in the alveolus
  • Augmenting alveolar ventilation, drawing more second gas in
• This accelerates induction when N2O is used alongside a volatile agent.

3. Alveolar Ventilation (Minute Ventilation)

• Increased minute ventilation raises FA more rapidly by delivering more anesthetic to the alveoli.
• This effect is most pronounced with highly soluble agents (e.g., halothane, isoflurane) because the blood absorbs more of the delivered drug. Hyperventilation therefore accelerates induction most with soluble agents.
• For poorly soluble agents (desflurane, N2O), ventilation has a smaller effect because uptake is already minimal.
• Controlled ventilation vs. spontaneous breathing: in spontaneous breathing, soluble agents cause CNS depression → reduced ventilation → negative feedback limiting further uptake (a degree of self-limitation). Under controlled ventilation this safety brake is removed.

4. Diffusion Capacity Across the Alveolar Membrane

• Normally, diffusion is not a rate-limiting step in healthy lungs.
• Disease (pulmonary fibrosis, pulmonary edema) can impair diffusion and slow uptake.
• Diffusion hypoxia (Fink effect): On discontinuation of N2O, the large volume of N2O diffusing from blood into alveoli can dilute alveolar O2 and CO2, causing hypoxia and washing out CO2.

II. FACTORS AFFECTING UPTAKE BY BLOOD (Three Key Determinants)

1. Solubility in Blood - Blood/Gas Partition Coefficient (λb/g)

• Low λb/g (sevoflurane, desflurane, N2O): Blood takes up little agent → FA rises quickly → rapid induction and emergence.
• High λb/g (halothane, isoflurane): Blood acts as a large reservoir → FA rises slowly → slow induction.
• Fat/blood partition coefficient > 1 means blood solubility increases with postprandial lipidemia; anemia decreases it.

2. Cardiac Output (Alveolar Blood Flow)

• Alveolar blood flow = cardiac output (in absence of pulmonary shunting).
• High cardiac output → more anesthetic absorbed from alveoli → FA rises more slowly → slower induction.
• Low cardiac output (shock, heart failure) → less uptake → FA rises rapidly → risk of overdose with soluble agents. This effect is less pronounced with insoluble agents.
• If cardiac output = 0, anesthetic uptake = 0.

3. Alveolar-to-Venous Partial Pressure Gradient (A-v difference)

• This gradient drives uptake from alveoli into blood.
• If venous blood returning to the lungs already has high anesthetic partial pressure (steady state), the gradient is small and uptake slows.
• This gradient depends on tissue uptake - if tissues extract large amounts of anesthetic from blood, the venous partial pressure remains low, maintaining a large gradient and sustaining pulmonary uptake.

III. TISSUE DISTRIBUTION - Four Tissue Groups

• VRG equilibrates first - brain, heart, liver equilibrate with arterial blood within minutes. This is why anesthesia onset is rapid.
• Muscle group sustains uptake for hours, acting as a reservoir that gradually fills.
• Fat group: Enormous capacity (fat/blood solubility × large volume) means it approaches equilibrium over days - contributes to prolonged emergence after very long anesthetics, especially with soluble agents.
• Transfer of anesthetic from blood to each tissue is governed by:
  1. Tissue/blood partition coefficient (solubility in tissue)
  2. Tissue blood flow
  3. Arterial-to-tissue partial pressure difference

IV. FACTORS AFFECTING ALVEOLAR CONCENTRATION - SUMMARY TABLE

V. MINIMUM ALVEOLAR CONCENTRATION (MAC)

• Increasing age (MAC decreases ~6% per decade; a 70-year-old has ~25% lower MAC than a 30-year-old)
• Hypothermia
• Hyponatremia
• Pregnancy (↑ progesterone)
• Opioids, sedatives, α2 agonists (additive/synergistic effects)
• Hypotension (MAP <50 mmHg)
• Nitrous oxide (MAC is additive - 0.5 MAC N2O + 0.5 MAC sevoflurane = 1 MAC)

• Hyperthermia
• Hypernatremia
• Chronic alcohol use
• Infancy (MAC is highest in neonates/infants)
• Hyperthyroidism

Sevoflurane - Pharmacodynamics and Complications

Physical Properties

• Type: Fluorinated methyl isopropyl ether
• Blood/gas partition coefficient: 0.65 (low - favors rapid induction/emergence)
• MAC: 2.0% (adults), higher in children
• Non-pungent, non-irritating to airways - ideal for inhalational induction
• Modest vapor pressure - conventional variable bypass vaporizer is sufficient
• Inhalation induction: 4-8% sevoflurane in 50% N2O/O2 achieves induction within ~1 minute

A. Cardiovascular Effects

• Myocardial contractility: Mildly depressed (dose-dependent negative inotropy)
• Systemic vascular resistance (SVR): Mildly decreased, slightly less than isoflurane or desflurane
• Arterial blood pressure: Mild decrease
• Heart rate: Little to no increase (unlike isoflurane/desflurane which cause reflex tachycardia) → cardiac output is not as well maintained
• QT interval: May prolong the QT interval; clinical significance uncertain. Prolongation may persist up to 60 minutes after emergence in infants
• Catecholamine sensitization: Does NOT sensitize the myocardium to catecholamine-induced arrhythmias (unlike halothane)
• Coronary preconditioning: Provides ischemic preconditioning via KATP channel opening, reducing ischemia-reperfusion injury - potentially cardioprotective in CABG surgery

B. Respiratory Effects

• Depresses respiration (decreases tidal volume, increases respiratory rate - net decrease in minute ventilation and alveolar ventilation)
• Significantly lower minute ventilation and respiratory frequency compared to halothane, with less thoracoabdominal asynchrony
• Reverses bronchospasm (bronchodilator) - useful in asthmatic patients; similar efficacy to isoflurane
• Non-pungent → does not trigger breath-holding, coughing, or laryngospasm → preferred for inhalational induction

C. Cerebral Effects

• Slightly increases cerebral blood flow (CBF) and intracranial pressure (ICP) at normocarbia (some studies show slight decrease in CBF)
• At concentrations >1.5 MAC, may impair CBF autoregulation (slightly less pronounced than isoflurane)
• At high concentrations with hypocapnia, can produce EEG spike-and-wave activity (epileptiform patterns), particularly in children - this is the most clinically relevant concern. However, frank seizure activity has not been consistently confirmed
• Decreases cerebral metabolic oxygen requirements (CMRO2)

D. Neuromuscular Effects

• Potentiates non-depolarizing neuromuscular blocking agents (NMBAs) - reduces the required dose
• Does not trigger malignant hyperthermia at standard doses (but is a triggering agent in susceptible patients - see contraindications)

E. Renal Effects

• Slightly decreases renal blood flow
• Metabolized to inorganic fluoride (F⁻) - elevated serum fluoride (>50 μmol/L) in ~7% of patients but clinically significant renal dysfunction has NOT been demonstrated with sevoflurane
• Overall metabolism rate: ~5% (10x isoflurane but much less than halothane at 20%)

F. Hepatic Effects

• Decreases portal vein blood flow but increases hepatic artery blood flow → total hepatic blood flow and O2 delivery maintained
• Generally not associated with immune-mediated hepatotoxicity (unlike halothane hepatitis)

Biotransformation & Toxicity (Complications)

1. Fluoride Nephrotoxicity

• CYP450 2E1 metabolizes sevoflurane → inorganic fluoride (F⁻) + hexafluoroisopropanol
• Serum [F⁻] >50 μmol/L in ~7% patients, yet no association with renal dysfunction has been confirmed in clinical studies
• The site of fluoride production (intrarenal vs. extrarenal) may explain why sevoflurane does not cause methoxyflurane-type nephrotoxicity despite similar peak fluoride levels

2. Compound A (Nephrotoxicity in Rats Only)

• Sevoflurane is degraded by CO2 absorbents (soda lime, barium hydroxide lime - NOT calcium hydroxide) to Compound A (fluoromethyl-2,2-difluoro-1-[trifluoromethyl]vinyl ether)
• Compound A accumulation is increased by:
  • Low fresh gas flow (closed/low-flow circuit)
  • High CO2 absorbent temperature
  • Desiccated barium hydroxide (Baralyme)
  • High sevoflurane concentrations
  • Long duration of anesthesia
• Compound A is nephrotoxic in rats at high concentrations; no adverse effects in humans have been demonstrated
• Some clinicians recommend fresh gas flows ≥2 L/min for anesthetics lasting several hours as a precautionary measure

3. Hydrogen Fluoride (HF) Formation

• Sevoflurane can be degraded to HF by metal/environmental impurities in manufacturing equipment, glass bottles, and anesthesia machines
• HF causes acid burns to respiratory mucosa on contact
• Risk substantially reduced by:
  • Adding water to sevoflurane during manufacturing
  • Packaging in special plastic containers

4. Fires in CO2 Absorbent

• Isolated reports of fire in anesthesia machine breathing circuits with desiccated CO2 absorbent when sevoflurane is used
• Risk factors: dry absorbent, high concentrations, prolonged contact
• Prevention: regular absorbent replacement and humidification

5. Malignant Hyperthermia (MH)

• Sevoflurane is a triggering agent for MH in susceptible individuals
• Contraindicated in patients with known MH susceptibility or family history

6. Neurotoxicity (Emerging Concern)

• Animal data and some human data suggest volatile anesthetics may contribute to apoptotic neurodegeneration in developing brains and tau hyperphosphorylation (Alzheimer risk)
• FDA investigation ongoing; single brief exposures in children are unlikely to cause harm per current consensus
• Mitigation: dexmedetomidine (possibly neuroprotective), minimizing exposure duration and concentration

7. EEG/Seizure-Like Activity

• At high concentrations or with hypocapnia, sevoflurane can produce epileptiform EEG patterns, especially in pediatric patients
• Clinical significance and whether this represents true seizure activity remains debated

Contraindications to Sevoflurane

1. Severe hypovolemia (cardiovascular depression + vasodilation → severe hypotension)
2. Known susceptibility to malignant hyperthermia
3. Raised intracranial pressure (increases CBF/ICP, impairs autoregulation at high MAC)

Drug Interactions

• Potentiates all non-depolarizing NMBAs (dose reduction required)
• Does NOT sensitize myocardium to catecholamines (epinephrine can be used safely)
• MAC additive with N2O, opioids, sedatives, dexmedetomidine → allows dose reduction
• CYP2E1 induction by ethanol or phenobarbital → increased fluoride production
• Combination with other QT-prolonging drugs warrants monitoring

• Morgan and Mikhail's Clinical Anesthesiology, 7e - Chapter 8 (Inhaled Anesthetics), pp. 281-315
• K.J. Lee's Essential Otolaryngology - Inhalation Agents section
• Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e - Sevoflurane sections
• Miller's Anesthesia, 10e - Sevoflurane, Compound A and Renal Toxicity

Short Notes on Inhaled Anesthetics for MD Anaesthesia

1. NITROUS OXIDE (N₂O)

Manufacture

NH₄NO₃ → N₂O + 2H₂O

Key Physical Properties

Pharmacodynamics

• Mechanism: NMDA receptor antagonism (glycine site); also activates opioid receptors and descending noradrenergic pathways (analgesia)
• Analgesia: Potent analgesic - 70% N₂O ≈ 10-15 mg morphine IM; used for procedural pain (Entonox = 50:50 N₂O:O₂)
• Cardiovascular: Net sympathomimetic (stimulates SNS) - maintains or slightly increases BP and HR; offsets mild intrinsic myocardial depression. Increases pulmonary vascular resistance - avoid in pulmonary hypertension
• Respiratory: Modest increase in rate, decrease in tidal volume; markedly depresses hypoxic ventilatory drive even at low concentrations
• CNS: Increases CBF and ICP (when given alone); attenuated when combined with IV agents (propofol, opioids). Does not suppress EEG
• Neuromuscular: Does NOT relax skeletal muscle; does NOT potentiate NMBAs
• No organ toxicity (liver, kidney unaffected)
• MAC additive: 0.5 MAC N₂O + 0.5 MAC volatile = 1 MAC total

Deleterious Effects (Key Exam Points)

1. Expansion of Air-Filled Cavities

• Doubles a compliant space in ~10 minutes; triples in ~30 minutes
• Contraindicated in: Pneumothorax, pneumoencephalus, obstructed middle ear (risk of tympanic membrane rupture), bowel obstruction, intraocular air bubble (vitreoretinal surgery), pulmonary bullae, air embolism

2. Vitamin B₁₂ / Methionine Synthase Inactivation

• N₂O irreversibly oxidises cobalt in vitamin B₁₂ from Co⁺ to Co³⁺ → inactivates methionine synthase
• Methionine synthase converts homocysteine → methionine and is required for DNA synthesis (via tetrahydrofolate)
• Consequences:
  • Megaloblastic anaemia (bone marrow suppression)
  • Peripheral neuropathy and subacute combined degeneration
  • Elevated homocysteine → cardiovascular risk
  • Elevated homocysteine is now linked to increased MACE (cardiac events) - the ENIGMA-II trial concern
• Risk groups: Malnutrition, alcoholism, B₁₂ deficiency, ICU patients (prolonged exposure)
• Single anesthetic exposure: generally safe; repeated/prolonged exposure (>6 hours) causes clinical toxicity
• Not used as chronic analgesic or ICU sedative for this reason

3. Diffusion Hypoxia (Fink Effect)

• On discontinuation, large volumes of N₂O rapidly exit blood into alveoli, diluting O₂ and CO₂ → hypoxaemia + lowered ETCO₂
• Prevention: Administer 100% O₂ for ≥5 minutes at end of anesthesia

4. PONV

• N₂O is a major risk factor for postoperative nausea and vomiting - acts on opioid receptors in the CTZ
• Avoiding N₂O reduces PONV incidence significantly (IMPACT trial)

5. Environmental / Greenhouse Effects

• Potent greenhouse gas (N₂O is ~300× CO₂ for global warming potential)
• Depletes stratospheric ozone
• Now increasingly discouraged in environmentally-conscious anaesthetic practice

6. Teratogenicity (Theoretical)

• Inactivation of methionine synthase → impaired DNA synthesis
• Contraindicated in first trimester of pregnancy; avoid in theatre staff with chronic exposure (occupational hazard)

7. Entonox Separation ("Laminated Gas" Phenomenon)

• Entonox (50% N₂O + 50% O₂) at temperatures below -6°C (pseudocritical temperature) separates into liquid N₂O-rich layer and gaseous O₂-rich layer → patient receives initially high O₂, then hypoxic N₂O-rich mixture
• Prevention: Store above 10°C; invert and shake cylinder before use

2. ISOFLURANE

Manufacture

• Chemical name: 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether
• Synthesized from isopropyl alcohol via halogenation and fluorination steps
• Structurally identical to enflurane but differs in the arrangement of Cl, F atoms (structural isomers)
• Manufactured as a racemic mixture

Key Physical Properties

Pharmacodynamics

• Minimal left ventricular depression in vivo - cardiac output maintained by reflex tachycardia (partial baroreceptor preservation)
• Vasodilation → ↓ SVR → ↓ arterial BP
• Mild β-adrenergic stimulation → ↑ skeletal muscle blood flow
• Rapid increases in concentration → transient ↑ HR, BP, catecholamines
• Coronary steal (Flacke syndrome): dilates normal coronary arteries but not stenotic ones → theoretical steal; largely not clinically relevant today
• Does NOT sensitize myocardium to catecholamines (unlike halothane)

• Depresses respiration; less tachypnea vs. other agents → more pronounced fall in MV and ↑ PaCO₂
• Blunts hypoxic and hypercapnic ventilatory drives at 0.1 MAC
• Good bronchodilator (slightly less than halothane)
• Pungent odor → airway irritation, breath-holding, coughing, laryngospasm → NOT suitable for inhalational induction

• At >1 MAC: ↑ CBF and ICP (less than halothane; effect reversed by hyperventilation - no need to pre-hyperventilate unlike halothane)
• Reduces CMRO₂; at 2 MAC produces electrically silent EEG (isoelectric)
• No epileptiform activity

• Relaxes skeletal muscle; potentiates NMBAs
• Triggers malignant hyperthermia (MH) in susceptible patients

• ↓ renal blood flow, ↓ GFR, ↓ urinary output

• ↓ total hepatic blood flow but hepatic artery flow preserved → better hepatic O₂ supply than halothane
• Liver function tests usually normal
• Very rare immune-mediated hepatitis (trifluoroacetyl hapten formation) - much rarer than halothane hepatitis

Biotransformation & Deleterious Effects

• Metabolized ~0.2% → trifluoroacetic acid (TFA) by CYP2E1; minimal fluoride release
• Nephrotoxicity: extremely unlikely, even with enzyme inducers
• Prolonged ICU sedation (>24h, 0.1-0.6%): can produce toxic plasma fluoride levels
• Isoflurane linked to possible ↑ postoperative cognitive dysfunction (POCD) in elderly, and neurodegeneration in pediatric patients (under FDA investigation)
• Malignant hyperthermia trigger
• Carbon monoxide production from dry CO₂ absorbent (less than desflurane)

3. DESFLURANE

Manufacture

• Chemical name: 1,2,2,2-tetrafluoroethyl difluoromethyl ether
• Structurally identical to isoflurane except a fluorine atom replaces the chlorine atom (desfluorination of isoflurane)
• This single substitution profoundly alters physical properties: extremely low boiling point (22.8°C), very high vapour pressure
• Synthesis involves fluorination of isoflurane precursors using HF under controlled conditions
• Requires specialized temperature-controlled, electrically-heated pressurized vaporizer (Tec 6 or equivalent) because:
  • Vapour pressure at 20°C = 669-681 mmHg (near atmospheric)
  • Would boil at room temperature at high altitudes

Key Physical Properties

Pharmacodynamics

• Similar to isoflurane: ↓ SVR → ↓ BP; cardiac output relatively maintained
• Moderate tachycardia (more than isoflurane)
• Rapid increases in concentration cause pronounced, transient ↑↑ HR, ↑↑ BP, ↑↑ catecholamines - more marked than with isoflurane, especially in patients with cardiovascular disease
  • This sympathoadrenal response (tracheal intubation-like reaction) can be attenuated by fentanyl, esmolol, or clonidine
• Does NOT sensitize myocardium to catecholamines (epinephrine safe up to 4.5 mcg/kg)

• ↓ tidal volume, ↑ respiratory rate → ↓ alveolar ventilation → ↑ PaCO₂
• Depresses ventilatory response to ↑ PaCO₂
• Very pungent and airway-irritating: causes salivation, breath-holding, coughing, laryngospasm, ↑ airway resistance in reactive airways
• Absolutely NOT suitable for inhalational induction (especially in children)

• Vasodilates cerebral vasculature → ↑ CBF, ↑ cerebral blood volume, ↑ ICP at normocapnia
• CMRO₂ decreased; CBF autoregulation maintained at low concentrations; CBF responsive to PaCO₂
• Desflurane-induced hypotension (MAP 60 mmHg): CBF still adequate to maintain aerobic metabolism

• Potentiates NMBAs (same as isoflurane)
• Triggers MH in susceptible patients

• Ultra-rapid emergence due to extremely low λb/g (50% faster wake-up vs. isoflurane)
• However: emergence delirium in some pediatric patients
• Rapid emergence does NOT translate to earlier PACU discharge (PACU readiness is multifactorial)

Biotransformation & Deleterious Effects

• Minimal metabolism (<0.02%): essentially inert in vivo; negligible fluoride production
• Carbon monoxide (CO) production: Desflurane is the most significant CO producer among volatile agents when CO₂ absorbent is desiccated (especially barium hydroxide lime / Baralyme; also soda lime with NaOH/KOH). CO poisoning under GA is difficult to diagnose - look for unexplained ↓ SpO₂ or carboxyhemoglobin on ABG
  • Prevention: Avoid desiccated absorbent; use calcium hydroxide lime (Amsorb); replace absorbent after weekends/long non-use
• Highest ozone-depleting potential of all inhalational anesthetics (global warming potential ~2500× CO₂ for 100 years); increasingly restricted/banned in some countries
• Sympathoadrenal surge on rapid uptitration - deleterious in ischaemic heart disease
• Emergence delirium in paediatric patients

4. XENON

Manufacture

• Xenon is a noble (inert) gas, Group 18 of the periodic table
• Naturally occurring minor constituent of atmospheric air (~90 parts per billion = 0.0000086% of air)
• Produced by fractional distillation of cryogenically liquefied air - the same industrial process used to produce oxygen and nitrogen, but xenon is collected as a trace byproduct
• Extremely energy-intensive and expensive process (>$10/litre of gas)
• Production of xenon itself generates significant CO₂ as a byproduct of the energy used
• Stored as a compressed gas; has unlimited shelf life; undergoes no reaction with CO₂ absorbents or UV light; non-flammable, non-explosive

Key Physical Properties

Pharmacodynamics

• Mechanism: Primarily NMDA receptor antagonism (competes with glycine at the glycine co-agonist site) - similar to ketamine/N₂O but more potent and selective; also activates two-pore domain K⁺ channels (TREK-1)
• Onset/Emergence: Ultra-rapid (λb/g = 0.115 → emergence 2-3× faster than N₂O); approaches the ideal anesthetic kinetics
• Cardiovascular: Minimal myocardial depression; not arrhythmogenic; minimal effects on hepatic and renal function. Maintains haemodynamic stability remarkably well
• Analgesia: Like N₂O, has significant analgesic activity; reduces intraoperative opioid requirements
• Neuroprotection: In preclinical models, xenon is consistently cardioprotective and neuroprotective against ischemia-reperfusion injury (KATP channel mechanism, anti-apoptotic via NMDA inhibition, ↓ calcium influx). Clinical trials in cardiac surgery patients show reduced pressor requirements and modest organ protection; however, does NOT improve survival or neurocognitive outcomes significantly in current RCTs
• Less postoperative delirium vs. sevoflurane in off-pump CABG surgery (clinical trial data)
• No malignant hyperthermia trigger; no organ toxicity; no metabolism
• No ozone depletion (natural element; does not react with atmospheric chemistry)

Deleterious Effects / Limitations

Comparative Summary Table

• Morgan and Mikhail's Clinical Anesthesiology, 7e, Ch. 8 (pp. 280-315)
• Miller's Anesthesia, 10e (Xenon section, pp. 2017-2019)
• Goodman & Gilman's Pharmacological Basis of Therapeutics (N₂O side effects, p. 1366)
• Barash, Cullen and Stoelting's Clinical Anesthesia, 9e

Second Gas Effect - Short Note for MD Anaesthesia Exam

Definition

Background: Concentration Effect (Prerequisite)

1. Concentrating effect: As gas molecules are absorbed, alveolar volume shrinks → the remaining gas molecules are concentrated into a smaller volume → alveolar concentration rises disproportionately
2. Augmented inflow effect: The fall in alveolar volume creates a slight sub-atmospheric pressure → fresh gas is drawn in from the circuit to replace absorbed gas → this inflow brings in additional anesthetic at the original inspired concentration → further elevates FA

Mechanism of the Second Gas Effect

Step-by-Step Mechanism (Numerical Example)

• 2 parts sevoflurane
• 70 parts N₂O
• 28 parts O₂
• Total = 100 parts

• 2 parts sevoflurane
• 35 parts N₂O (remaining)
• 28 parts O₂
• Total = 65 parts

• New inflow contains: 0.7 parts sevoflurane, 24.5 parts N₂O, 9.8 parts O₂
• New alveolar sevoflurane = (2 + 0.7)/100 = 2.7%

The Two Mechanisms Acting on the Second Gas:

Graphical Representation

• Effect is present for both poorly soluble (sevoflurane, desflurane - upper pair) and highly soluble (halothane - lower pair) agents
• The second gas effect is more pronounced for highly soluble agents - because they have more room to benefit from accelerated uptake (their FA would otherwise rise very slowly)
• The boost is modest but consistent

Conditions Necessary for the Second Gas Effect

1. The first gas must be administered in high concentration - N₂O is uniquely suited (50-70% used clinically). No other clinical agent can fill this role at comparable concentrations
2. The first gas must be rapidly and extensively taken up from alveoli - N₂O's high inspired partial pressure drives this despite its low solubility
3. A second gas must be present simultaneously in the alveolar gas mixture

Clinical Role in Anaesthesia

1. Faster Induction

• By elevating alveolar partial pressure of the volatile agent more rapidly, the second gas effect theoretically speeds induction
• Practically relevant at the start of induction, when N₂O uptake is greatest (before alveolar N₂O equilibrates)
• As N₂O equilibration approaches, the effect wanes (once A-v gradient for N₂O narrows, less N₂O is absorbed per unit time)

2. Acceleration of O₂ Uptake

• O₂ is also a "second gas" - the augmented inflow effect draws O₂ in as well, slightly increasing alveolar and arterial PO₂ transiently during N₂O induction

3. Reduction in Volatile Agent Requirements

• By raising FA of the volatile agent faster, N₂O allows use of a lower inspired concentration of volatile agent to achieve the same alveolar partial pressure at a given time point
• This reduces circulatory depression and other concentration-related side effects

4. MAC Additivity

• N₂O contributes to total MAC (MAC additive): 0.5 MAC N₂O + 0.5 MAC sevoflurane = 1 MAC total
• This is a separate, clinically larger benefit of N₂O co-administration compared to the second gas effect per se

Is the Second Gas Effect Clinically Significant? (Controversy)

Reverse Second Gas Effect (Diffusion Hypoxia)

• On discontinuation of N₂O, large volumes of N₂O rapidly exit blood into alveoli
• This dilutes alveolar O₂ and other gases (including volatile agent) - the volatile agent is washed out faster
• This accelerates emergence from volatile anesthesia when N₂O is stopped simultaneously
• Simultaneously, alveolar O₂ is diluted → diffusion hypoxia (Fink effect) if supplemental O₂ is not given
• Prevention: Administer 100% O₂ for ≥5 minutes at end of N₂O anaesthesia

Summary Points for Exam

• Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 286
• Barash, Cullen and Stoelting's Clinical Anesthesia, 9e, pp. 1394-1395
• Miller's Anesthesia, 10e, pp. 1947-1948
• Goodman & Gilman's Pharmacological Basis of Therapeutics
• Epstein RM et al. Anesthesiology 1964;25:364 (original description)
• Peyton PJ et al. Anesthesiology 2008;108:381 (clinical measurement)